InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,949.20
(
0.43%
)
Dow Jones
43,444.99
(
-0.70%
)
Brent Oil
71.39
(
0.97%
)
Bitcoin
91,094.47
(
1.37%
)
Post# of 253651
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120736
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 171040

Tuesday, 12/10/2013 4:09:43 PM

Tuesday, December 10, 2013 4:09:43 PM

Post# of 253651
ABBV/ENTA’s SAPHIRE-2 data (#msg-94817670) are so strong that, realistically, GILD can only hope to match them rather than exceed them.

No one I know expected a 96% SVR rate in this patient pool (treatment-experienced GT1a/GT1b of whom 49% were prior null responders) without any hint of a safety or tolerability problem.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up